Neuroscience trends signal a competitive shift toward stronger clinical evidence and practical treatment value, as oral BTK inhibitors, CAR T-cell therapy, simplified drug administration and Alzheimer’s trial setbacks reshape therapeutic differentiation and market positioning.
Coverage period: 29 September – 3 November, 2026
Introduction
October’s 2026 defining neuroscience story was the emergence of more demanding competitive standards in multiple sclerosis (MS), where advancing oral BTK inhibitors brought disability outcomes, safety and treatment flexibility closer to the center of therapeutic differentiation.
Alongside this development, early CAR T-cell data introduced another potential approach to progressive disease, while regulatory approvals in schizophrenia and generalized myasthenia gravis demonstrated the commercial relevance of simpler treatment administration. Setbacks in Alzheimer’s disease provided a contrasting reminder that biological rationale must translate into meaningful clinical benefit.
Together, these developments highlight how clinical evidence, treatment burden and practical patient value are shaping the next phase of neuroscience competition.
Companies covered: Roche, Novartis, TG Therapeutics, Teva Pharmaceuticals, UCB, Eli Lilly, Acumen Pharmaceuticals
Diseases covered: Multiple sclerosis (MS), Relapsing multiple sclerosis (RMS), Primary progressive multiple sclerosis (PPMS), Progressive MS, Generalized myasthenia gravis (gMG), Schizophrenia / psychotic disorders, Alzheimer’s disease
Executive Summary
- Multiple sclerosis competition enters a new phase as oral BTK inhibitors advance. Roche’s fenebrutinib received FDA priority review across relapsing and primary progressive MS, while Novartis reported positive Phase III results for remibrutinib in relapsing MS. Their progress could expand high-efficacy oral treatment options, with disability outcomes, hepatic safety and approved indications likely to influence competitive positioning.
- Allogeneic CAR T-cell therapy opens a potential new direction in progressive MS. Early Phase I findings for TG Therapeutics’ azer-cel demonstrated B-cell depletion and preliminary disability stabilization in previously treated patients. The results support further investigation of cell-based immune intervention, although durability, comparative efficacy and long-term safety remain unproven.
- Administration innovation strengthens differentiation in chronic neurological and psychiatric conditions. FDA approvals for Teva’s once-monthly injectable olanzapine and UCB’s zilucoplan autoinjector highlight the importance of treatment convenience. Simplified administration may influence patient preference, clinical workflows and treatment persistence, but real-world adoption and outcome benefits remain uncertain.
- Alzheimer’s disease development faces continued pressure to demonstrate clinical benefit. The discontinuation of Eli Lilly’s mevidalen program and Acumen’s sabirnetug following disappointing Phase II outcomes reinforces the risks of advancing therapies without convincing cognitive or functional improvements. These setbacks may encourage greater scrutiny of clinical endpoints, translational evidence and portfolio concentration.
Watch the video summary
Our Strategic Perspective on Four Competitive Shifts Reshaping Neuroscience
Multiple Sclerosis: Oral BTK Inhibitors Intensify Competition on Disability and Safety
The advancement of two oral BTK inhibitors marks an important competitive development in multiple sclerosis. Both programs demonstrated meaningful relapse reductions, but their broader significance lies in the possibility of expanding treatment choices while addressing disability progression.
Roche’s fenebrutinib reduced annualized relapse rates by 51.1% and 58.5% versus teriflunomide in the Phase III FENhance trials. In primary progressive MS, FENtrepid met its non-inferiority endpoint against Ocrevus, with a numerical 12% reduction in disability progression risk.
Novartis’ remibrutinib reduced annualized relapse rates by 35.2% and 31.2% versus teriflunomide across REMODEL-1 and REMODEL-2. A pooled analysis also showed a nominally significant 29.2% reduction in six-month confirmed disability progression.
Although cross-trial efficacy comparisons are inappropriate, the programs present different potential competitive advantages.
Fenebrutinib’s development across relapsing and primary progressive disease could support broader clinical positioning if approved. Remibrutinib’s reported absence of a liver safety signal may offer differentiation within a therapeutic class facing heightened hepatic safety scrutiny.
Market implication: Oral BTK inhibitors could challenge existing MS treatment pathways by combining substantial relapse control with convenient administration. Competitive success will depend on disability outcomes, long-term tolerability and the populations included in regulatory approvals.
Key uncertainty: Fenebrutinib’s liver enzyme elevations and reported fatality imbalance require careful regulatory assessment. Remibrutinib’s disability findings also need interpretation alongside the nominal significance of pooled analyses. Neither program has yet established its eventual real-world position against established high-efficacy therapies.
Progressive Multiple Sclerosis: Allogeneic CAR T-Cell Therapy Tests a New Immune Intervention Strategy
Progressive MS remains a major area of unmet need, particularly for patients experiencing disability progression despite high-efficacy treatment. Early clinical investigation of allogeneic CAR T-cell therapy introduces a potentially different approach to immune intervention.
TG Therapeutics reported Phase I results for azer-cel, an investigational CD19-directed allogeneic CAR T-cell therapy, in 26 patients with progressive MS. All participants had previously received anti-CD20 treatment and experienced progression despite high-efficacy therapies.
At Day 90, 89% of evaluable patients (16 of 18) had stable or improved disability scores. Investigators also observed B-cell depletion in peripheral blood and cerebrospinal fluid, indicating biological activity. No high-grade CAR T-associated toxicities were reported in the initial analysis.
These findings support continued investigation of a cell-based approach that may offer an alternative to conventional ongoing immune modulation.
An allogeneic, potentially off-the-shelf platform could also provide practical advantages over individualized cell manufacturing, although these remain theoretical in the MS setting.
Market implication: If subsequent studies establish durable clinical benefit and acceptable safety, CAR T-cell therapy could emerge as a distinct treatment approach for selected patients with progressive disease inadequately controlled by existing therapies.
Key uncertainty: The open-label study included few patients and had a median follow-up of only 4.9 months. Disability stabilization cannot yet be confidently attributed to treatment. Longer follow-up, controlled trials and evidence of sustained benefit will be essential before its therapeutic and commercial potential can be assessed.
Schizophrenia and Myasthenia Gravis: Drug Delivery Innovation Creates Commercial Differentiation
October’s regulatory approvals showed how improvements in administration can create additional value for established therapies without requiring a new therapeutic mechanism.
In schizophrenia, Teva received FDA approval for WELTRUZA, a once-monthly subcutaneous formulation of olanzapine that requires neither oral supplementation nor post-injection monitoring. The formulation addresses practical limitations that can complicate treatment delivery and long-term medication management.
In generalized myasthenia gravis, UCB obtained FDA approval for a ZILBRYSQ autoinjector, providing another self-administration option for eligible adults. Supporting evidence demonstrated complete dose delivery in 99.8% of assessed administrations, with high reported patient satisfaction.
Although these products serve different populations, both developments show how treatment administration can become a competitive consideration alongside established efficacy and safety.
Reduced administration complexity may affect patient preferences, healthcare professional workflows and the resources needed to support ongoing treatment.
For pharmaceutical companies, device and formulation innovation may also offer opportunities to strengthen product positioning and extend the relevance of established therapeutic mechanisms.
Market implication: Convenience, administration flexibility and patient support could play a greater role in commercialization, particularly in chronic conditions where treatment burden influences care decisions.
Key uncertainty: The available evidence does not establish that these improvements produce superior long-term adherence, persistence or clinical outcomes. Commercial uptake, reimbursement conditions and real-world utilization will determine whether the practical advantages translate into sustained market differentiation.
Alzheimer’s Disease: Clinical Failures Sharpen Evidence and Portfolio Strategy
Two Alzheimer’s disease program discontinuations reinforced the challenge of translating mechanistic hypotheses into meaningful cognitive and functional benefits.
Eli Lilly discontinued its Phase II mevidalen program in symptomatic Alzheimer’s disease after the treatment failed to meet internal expectations. Detailed trial outcomes were not disclosed, limiting conclusions about the underlying reasons for the decision.
Acumen Pharmaceuticals terminated sabirnetug development after the Phase II ALTITUDE-AD trial failed to demonstrate meaningful cognitive or functional improvement versus placebo at 18 months.
Sabirnetug’s failure is particularly informative because it targeted soluble amyloid-beta oligomers, a differentiated approach intended to address a potentially important driver of neurodegeneration.
The outcome does not invalidate other amyloid-directed approaches, but it illustrates the difficulty of converting target-specific biological hypotheses into demonstrated patient benefit.
The contrasting corporate consequences also highlight portfolio risk. Acumen’s dependence on a single clinical asset exposed it to significant strategic uncertainty, while Lilly retains a diversified neuroscience portfolio supported by acquisitions and partnerships.
Market implication: Clinical development and investment decisions may place greater weight on robust patient-centered endpoints, translational evidence and portfolio diversification. Developers will need to demonstrate how differentiated mechanisms improve outcomes rather than relying on biological rationale alone.
Key uncertainty: The available results do not establish whether these failures reflect target limitations, treatment design, patient selection or other factors. Further clinical disclosures will be important for interpreting their implications for future Alzheimer’s programs.
What We Are Watching Next in Neuroscience Market Competition
- MS regulatory positioning: FDA review of fenebrutinib and planned global submissions for remibrutinib could clarify the future role of oral BTK inhibitors and the breadth of their approved indications.
- BTK inhibitor safety and disability evidence: Regulatory interpretation of hepatic findings and longer-term disability outcomes will influence clinical differentiation.
- CAR T-cell durability in progressive MS: Additional azer-cel follow-up and dose-escalation results will help determine whether preliminary biological and disability signals translate into sustained benefit.
- Real-world adoption of administration innovations: WELTRUZA’s US launch and the planned Q1 2027 introduction of the ZILBRYSQ autoinjector will offer early evidence of demand for simplified treatment options.
- Alzheimer’s development reassessment: Further mevidalen disclosures and Acumen’s strategic review may provide insight into future development priorities and portfolio risk management.
Key Takeaway: Clinical Evidence and Treatment Practicality Redefine Neuroscience Competition
October’s neuroscience developments place multiple sclerosis at the center of an emerging competitive shift, as oral BTK inhibitors approach regulatory decisions and cell-based treatments begin testing new approaches to progressive disease.
Beyond MS, administration innovations demonstrate that practical treatment advantages can create additional commercial value, while Alzheimer’s failures reinforce the importance of convincing clinical outcomes.
The defining implication is that competitive positioning will depend less on mechanism or efficacy claims in isolation and more on the combination of meaningful patient benefit, safety, treatment practicality and credible supporting evidence.
For developers and commercial teams, demonstrating that combination will be central to establishing durable differentiation in neuroscience.
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com